What 503A and 503B actually mean
Published 2026-07-11 · No medical advice · Not sponsored by any clinic or pharmacy
Two regulatory categories that determine where your medication is made and what oversight applies.
You'll see "503A" and "503B" on almost every compounding pharmacy's site, usually without explanation. Both refer to sections of the federal Food, Drug and Cosmetic Act that exempt certain compounded drugs from the normal FDA new-drug approval process, under two different sets of rules.
503A: patient-specific compounding
A 503A pharmacy compounds a specific preparation against a specific, valid prescription for a named patient. It's the traditional compounding-pharmacy model: your clinician sends a prescription, the pharmacy makes that exact preparation for you. 503A pharmacies are licensed and inspected primarily at the state level, by the state board of pharmacy, with the FDA retaining oversight but not routine inspection authority in the way it has over 503B facilities.
503B: outsourcing facilities
A 503B outsourcing facility can compound in larger batches, ahead of a specific prescription ("office stock"), under current Good Manufacturing Practice (cGMP) standards, closer to how a drug manufacturer operates. In exchange for that latitude, 503B facilities must register with the FDA and are subject to routine risk-based FDA inspections, the kind that produce the Form 483s and warning letters referenced elsewhere on this site.
Which one is "better"?
Neither category is inherently safer; the categories describe different operating models with different oversight mechanisms attached. What should raise a flag is a pharmacy that is vague about which one it is, or that describes itself in manufacturing terms (batch production, wide multi-state distribution) while registered and operating only as a 503A. That mismatch between claimed scale and registered category is one of the more reliable tells in this industry, and it's exactly the kind of gap we look for when we review a pharmacy.
Why compounded GLP-1s exist at all
Compounding of a drug that duplicates an FDA-approved product (like brand-name tirzepatide or semaglutide) is only permitted under federal law while that drug is listed on the FDA's drug shortage list, or in limited cases where a compounded variation (a different strength, a different form, an added ingredient) is clinically justified for a specific patient. As shortage status changes, the legal footing for compounded versions of a given medication can change with it. It's worth checking the current FDA drug shortage database if you want to understand why a compounded version is being offered to you at all.
"503A" or "503B" on its own tells you a regulatory category, not a safety verdict. Ask which one, then check whether the pharmacy's actual conduct, scale, and disclosures match that category.